Physician profile
Phi-Van T Le
NPI 1063462463
$8,413.98
in general payments reported to CMS, 2019-2025
37 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $637 · 2021: $1,124 · 2022: $1,113 · 2023: $1,046 · 2024: $1,668 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,255 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.19 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.33 | 2020-2025 | |
| Pfizer INC. | $1,062.95 | 2019-2025 | |
| Leo Pharma INC. | $548.93 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $532.22 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $458.05 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $406.98 | 2019-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $376.05 | 2019-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $357.11 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $343.46 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Janssen Biotech, INC. | $334.48 | 2020-2025 | Tremfya |
| Amgen INC. | $325.43 | 2019-2025 | Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $304.71 | 2021 | |
| Journey Medical Corporation | $277.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.71 | 2022-2024 | Sotyktu |
| Incyte Corporation | $173.09 | 2021-2025 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $165.45 | 2021-2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $145.63 | 2023-2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $142.47 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $106.32 | 2019 | |
| Sebela Pharmaceuticals INC. | $90.82 | 2019-2023 | Naftin |
| Mayne Pharma Commercial LLC | $89.83 | 2019-2023 | |
| Almirall LLC | $89.82 | 2019-2023 | Seysara |
| Celgene Corporation | $79.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $63.62 | 2021-2022 | |
| Dermavant Sciences, INC. | $51.99 | 2023 | Vtama |
| Ani Pharmaceuticals, INC. | $40.09 | 2025 | Oxistat |
| Nabriva Therapeutics, Plc | $37.00 | 2022 | |
| Mylan Pharmaceuticals INC. | $36.32 | 2019 | |
| Organon LLC | $34.20 | 2025 | Vtama |
| Dermira, INC. | $33.45 | 2019-2020 | |
| Medtronic, INC. | $28.58 | 2024 | Closurefast |
| Glenmark Therapeutics INC. | $27.00 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $21.26 | 2019-2020 | |
| Lnhc, INC | $20.08 | 2025 | Zelsuvmi |
| Epi Health, LLC | $19.70 | 2020 | |
| Aclaris Therapeutics, INC. | $16.89 | 2019 | |
| Tempus Ai, INC | $16.29 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phi-Van Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.